Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2 immunotherapy and isotretinoin: a prospective Phase II study

References

• Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res 2012; 18:2423-8; PMID:22427348; http://dx.doi.org/10.1158/1078-0432.CCR-11-1409
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsey NK, Swift P, Shimada H, Black CT, Brodeur GM, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Eng J Med 1999; 341:1165-73; PMID:10519894; http://dx.doi.org/10.1056/NEJM199910143411601
   PubMed Web of Science ®Google Scholar
• De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21:1592-1601; PMID:12697885; http://dx.doi.org/10.1200/JCO.2003.05.191
   PubMed Web of Science ®Google Scholar
• Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6:649-58; PMID:16129365; http://dx.doi.org/10.1016/S1470-2045(05)70291-6
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 2008; 9:247-56; PMID:18308250; http://dx.doi.org/10.1016/S1470-2045(08)70069-X
   PubMed Web of Science ®Google Scholar
• Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial. Lancet Oncol 2013; 14:999-1008; PMID:23890779; http://dx.doi.org/10.1016/S1470-2045(13)70309-7
   PubMed Web of Science ®Google Scholar
• London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23:6459-65; PMID:16116153; http://dx.doi.org/10.1200/JCO.2005.05.571
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Eng J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992. Eur J Cancer 2000; 36:901-8; PMID:10785596; http://dx.doi.org/10.1016/S0959-8049(00)00058-7
   PubMedGoogle Scholar
• Castel V, Canete A, Melero C, Acha T, Navajas A, Garvia-Miguel P, Contra T, Molina J, Galaron P, Cruz O. Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol 2000; 35:724-6; PMID:11107156; http://dx.doi.org/10.1002/1096-911X(20001201)35:6%3c724::AID-MPO53%3e3.0.CO;2-U
   PubMedGoogle Scholar
• Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol/Oncol 2004; 26:227-32; PMID:15087949; http://dx.doi.org/10.1097/00043426-200404000-00003
   PubMed Web of Science ®Google Scholar
• Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer 2008; 112:2796-801; PMID:18429000; http://dx.doi.org/10.1002/cncr.23507
   PubMedGoogle Scholar
• Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D'Angelo P, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian Neuroblastoma Registry. Eur J Cancer 2009; 45:2835-42; PMID:19616426; http://dx.doi.org/10.1016/j.ejca.2009.06.010
   PubMed Web of Science ®Google Scholar
• London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Lehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011; 29:3286-92; PMID:21768459; http://dx.doi.org/10.1200/JCO.2010.34.3392
   PubMed Web of Science ®Google Scholar
• Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr Blood Cancer 2011; 56:578-83; PMID:21298742; http://dx.doi.org/10.1002/pbc.22693
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: Challenges on the road to precision therapy. J Pediatr Hematol Oncol 2013;35:337-347; PMID:23703550; http://dx.doi.org/10.1097/MPH.0b013e318299d637
   PubMed Web of Science ®Google Scholar
• Basta N, Makin G, Feltbower RG, Birch JM, Brown N, Elliott M, Ingham D, Moreno L, Baronne G, Pearson A, et al. Factors associated with recurrences and length of survival following relapse in UK patients with high risk neuroblastoma. Advances in Neuroblastoma Research Information Book, 2014; page 134
   Google Scholar
• Yeh SDJ, Larson SM, Burch L, Kushner BH, LaQuaglia M, Finn R, Cheung N-KV. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 1991; 32:769-76; PMID:1902508
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study. Int J Oncol 1998; 12:1299-1306; PMID:9592190
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung N-KV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19:4189-94; PMID:11709561
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Cheung IY, Kramer K, Modak S, Ostrovnaya I, Kuk D, Pandit-Taskar N, Chamberlain E, Kushner BH. Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 2014; 135:2199-205; PMID:24644014; http://dx.doi.org/10.1002/ijc.28851
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Kushner BH, Cheung IY, Canete A, Gerald W, Liu C, Finn R, Yeh SJ, Larson SM. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16:3053-60; PMID:9738575
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Cheung IY, Kushner BH, Ostrovnaya I, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012; 30:3264-270; PMID:22869886; http://dx.doi.org/10.1200/JCO.2011.41.3807
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung N-KV. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 2004; 10:84-7; PMID:14734455; http://dx.doi.org/10.1158/1078-0432.CCR-1147-3
   PubMedGoogle Scholar
• Yu A, Uttenreuther-Fischer MM, Huang C-S, Tsui CC, Gillies SD, Reisfeld RA, Kung FH. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16:2169-80; PMID:9626218
   PubMed Web of Science ®Google Scholar
• Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study. J Clin Oncol 2010; 28:4969-75; PMID:20921469; http://dx.doi.org/10.1200/JCO.2009.27.8861
   PubMed Web of Science ®Google Scholar
• Cheung N-KV, Cheung IY, Canete A, Yeh SJ, Kushner BH, Bonilla MA, Heller G, Larson SM: Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res 1994; 54:2228-33; PMID:8174131
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo HF, Heller G, Cheung IY: Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-GD2 antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000; 6:2653-60; PMID:10914706
   PubMed Web of Science ®Google Scholar
• Cheung IY, Hsu K, Cheung N-KV. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012; 30:426-32; PMID:22203761; http://dx.doi.org/10.1200/JCO.2011.37.6236
   PubMed Web of Science ®Google Scholar
• George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24:2891-6; PMID:16782928; http://dx.doi.org/10.1200/JCO.2006.05.6986
   PubMed Web of Science ®Google Scholar
• Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011; 29:4351-7; PMID:22010014; http://dx.doi.org/10.1200/JCO.2010.34.3293
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung N-KV. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006; 24:5271-6; PMID:17114661; http://dx.doi.org/10.1200/JCO.2006.06.7272
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung N-KV. High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer 2011; 56:403-8; PMID:21049517; http://dx.doi.org/10.1002/pbc.22855
   PubMed Web of Science ®Google Scholar
• Saylors, RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ; Pediatric Oncology Group: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463-9; PMID:11481351
   PubMed Web of Science ®Google Scholar
• Garavanta A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, Prete A, Mastrangelo S, Podda M, Haupt R et al, : A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003; 98:2488-94; PMID:14635085; http://dx.doi.org/10.1002/cncr.11797
   PubMedGoogle Scholar
• Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung N-KV. Ifosfamide, carboplatin, and etoposide for neuroblastoma: A high-dose salvage regimen and review of the literature. Cancer 2013; 119:665-71; PMID:22951749; http://dx.doi.org/10.1002/cncr.27783
   PubMed Web of Science ®Google Scholar
• Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006; 24:3423-30; PMID:16849757; http://dx.doi.org/10.1200/JCO.2005.03.9271
   PubMed Web of Science ®Google Scholar
• Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013; 14:472-80; PMID:23598171; http://dx.doi.org/10.1016/S1470-2045(13)70095-0
   PubMed Web of Science ®Google Scholar
• Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-oncol 2010; 97:409-18; http://dx.doi.org/10.1007/s11060-009-0038-7
   PubMed Web of Science ®Google Scholar
• Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012; 18:2740-53; PMID:22589483; http://dx.doi.org/10.1158/1078-0432.CCR-11-1939
   PubMed Web of Science ®Google Scholar
• Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J. Central nervous system metastases in neuroblastoma: Radiologic, clinical, and biological features in 23 patients. Cancer 2003; 98:156-65; http://dx.doi.org/10.1002/cncr.11448
   Web of Science ®Google Scholar
• Cheung N-KV, Dyer MA. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nature Rev Cancer 2013; 13:397-411; http://dx.doi.org/10.1038/nrc3526
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung N-KV. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res 2014; 20:1375-82; PMID:24520094; http://dx.doi.org/10.1158/1078-0432.CCR-13-1012
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung N-KV. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009; 27:1041-6; PMID:19171710; http://dx.doi.org/10.1200/JCO.2008.17.6107
   PubMedGoogle Scholar
• Navid F, Sondel PM, Barfield R, Shulkin BI, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim KM, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014; 32:1445-52; PMID:24711551; http://dx.doi.org/10.1200/JCO.2013.50.4423
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheung N-KV. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett 2014; 588:288-97; PMID:24295643; http://dx.doi.org/10.1016/j.febslet.2013.11.030
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77; PMID:8336186
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar